Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212203 | 0.83 | L3MBTL1 (0.39) | KMT2AMEN1AHRHTTSMN1; SMN2 | |
| SCHEMBL16963966 | 0.81 | KMT2A (0.39) | KMT2AMEN1AHRHTTPKM | |
| SCHEMBL6608600 | 0.81 | ALDH1A1 (0.42) | KMT2AMEN1AHRHTTSMN1; SMN2 | |
| SCHEMBL2215634 | 0.78 | CNR2 (0.47) | KMT2AMEN1AHRHTT | |
| SCHEMBL24553896 | 0.77 | HTT (0.50) | KMT2AHTTSMN1; SMN2LMNA | |
| SCHEMBL8262559 | 0.77 | HTT (0.53) | KMT2AMEN1AHRHTTSMN1; SMN2 | |
| SCHEMBL23361708 | 0.76 | KMT2A (0.36) | KMT2AMEN1AHRHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23354295 | 0.75 | KMT2A (0.35) | KMT2AMEN1AHRHTTSMN1; SMN2 | |
| SCHEMBL2521960 | 0.75 | KMT2A (0.48) | KMT2ASMN1; SMN2LMNA | |
| SCHEMBL23366891 | 0.74 | SMN1; SMN2 (0.35) | KMT2AMEN1AHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023159307-A1 | POLO-LIKE KINASE 4 (PLK4) INHIBITORS, PHARMACEUTICAL COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | REPARE THERAPEUTICS INC. (CA) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | KMT2A 2250/4885MEN1 468/4885AHR 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.